Immune Reactivity to Hepatitis B Vaccine among Individuals with Type 2 Diabetes
Published: 2023-08-23
Page: 196-204
Issue: 2023 - Volume 6 [Issue 1]
Sujal Kumar Bokshi *
District Hospital, Narail, Bangladesh.
Ashesh Chowdhury
Department of Immunology, BIRDEM, Dhaka, Bangladesh.
*Author to whom correspondence should be addressed.
Abstract
Background: The interaction between immune responses and vaccine efficacy in individuals with underlying health conditions is a topic of growing significance. In the realm of infectious diseases, the impact of Type 2 diabetes on immune reactions to vaccines, specifically the Hepatitis B vaccine, has garnered attention. This investigation delves into the intricate interplay between the immune system and vaccine-induced protection in Type 2 diabetic patients. By elucidating the unique dynamics of immune responses in this context, valuable insights can emerge, potentially paving the way for tailored vaccination strategies and improved healthcare outcomes for this vulnerable population.
Aim of the Study: This research aimed to investigate the immune reactions to the hepatitis B vaccine among individuals diagnosed with type 2 diabetes.
Methods: The study investigated immune responses to the hepatitis B vaccine in type 2 diabetic patients. Employing experimental design, participants were chosen through non-probability purposive sampling and divided into diabetic and non-diabetic groups. Key seromarkers (anti-HBs, IFN-γ, IL-2) were assessed after vaccination using approved analytics and correlated with diabetes duration. The research, conducted at the Bangladesh Institute of Research and Rehabilitation in Diabetes, involved 67 participants (33 diabetics, 34 non-diabetics) meeting inclusion criteria while excluding certain cases. Ethical approval was obtained, and participants provided informed consent. Serum samples were analyzed at specific post-vaccination days for different markers. Statistical analysis was employed, including Z and t-tests, Pearson's Correlation, and SPSS-17 software, with significance set at p < 0.05.
Results: The study compared various parameters between diabetic and non-diabetic groups after hepatitis B vaccination. Both groups had similar mean ages, serum bilirubin levels, ALT levels, and serum creatinine levels. Fasting plasma glucose was higher in diabetics. Gender distribution was comparable in both groups. Protective anti-HBs titers varied, with more low titers in diabetics and high titers in non-diabetics, but not statistically significant. Post-vaccination anti-HBs titers were lower in diabetics, yet not significantly. Notably, IFN-γ levels were significantly lower in diabetics, while IL-2 levels post-vaccination were similar. Overall, the study observed several differences but most were not statistically significant.
Conclusion: In conclusion, the study highlights that immune responses to the Hepatitis B vaccine in Type 2 diabetic patients may exhibit variations compared to non-diabetic individuals. Further research is imperative to understand these responses better, enabling the optimization of vaccination strategies for improved protection against Hepatitis B in this vulnerable population.
Keywords: Immune responses, hepatitis B vaccine, type 2 diabetic patients
How to Cite
Downloads
References
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53.
WHO 2009, Diabetes, Fact sheet N° 312. Available:http://www.who.int/mediacentre/factsheets/fs312/en/
IDF (International Diabetic Federation) 2009, Latest Diabetic Figures paint grim global picture.
Principles SS. Practice of medicine–edited by Nicolas A Boon, Nicki R Colledge, Brian R Walker John AA Hunter.
Sayeed MA, Hussain MZ, Banu A, Rumi MA, Khan AA. Prevalence of diabetes in a suburban population of Bangladesh. Diabetes research and clinical practice. 1997;34(3):149-55.
Rahim MA, Hussain A, Khan AA, Sayeed MA, Ali SK, Vaaler S. Rising prevalence of type 2 diabetes in rural Bangladesh: a population-based study. Diabetes research and clinical practice. 2007;77(2):300-5.
Hussain A, Rahim MA, Azad Khan AK, Ali SM, Vaaler S. Type 2 diabetes in rural and urban population: diverse prevalence and associated risk factors in Bangladesh. Diabetic Medicine. 2005;22(7):931-6.
WHO 2008, Hepatitis B, Fact sheet N°204, Retrieved 7 Jun 2010
Zaki MH, Darmstadt GL, Baten A, Ahsan CR, Saha SK. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. Journal of tropical pediatrics. 2003;49(6):371-4.
Rumi MA, Siddiqui MA, Salam MA, Iqbal MR, Azam MG, Chowdhury AK, Khan AY, Hasan KN, Hassan MS. Prevalence of infectious diseases and drug abuse among Bangladeshi workers. Southeast Asian Journal of Tropical Medicine & Public Health. 2000;31(3):571-4.
Gibney L, Saquib N, Metzger J, Choudhury P, Siddiqui MA, Hassan MS. Human immunodeficiency virus, hepatitis B, C and D in Bangladesh's trucking industry: prevalence and risk factors. International journal of epidemiology. 2001;30(4):878-84.
Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. Journal of Health, Population and Nutrition. 2000;145-50.
Sattar H, Islam MN. Hepatitis B virus markers among the prostitutes of Dhaka. Bangladesh Medical Research Council Bulletin. 1996;22(1):8-11.
Demir M, Serin E, Göktürk S, Ozturk NA, Kulaksizoglu S, Ylmaz U. The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. European Journal of Gastroenterology & Hepatology. 2008;20(7):668-73.
Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World journal of gastroenterology: WJG. 2009;15(3):280.
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533-9.
Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Annals of hepatology. 2008;7(2): 148-51.
Africa PN. Knowledge, attitudes and practices of health care workers regarding hepatitis B vaccination, in the Ekurhuleni Metro, Gauteng Province (Doctoral dissertation, University of Limpopo (Medunsa Campus)).
Alexiewicz JM, Kumar D, Smogorzewski M, Klin M, Massry SG. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Annals of internal medicine. 1995;123(12):919-24.
Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabetic Medicine. 1997;14(1):29-34.
Delespesse G, Duchateau J, Bastenie PA, Lauvaux JP, Collet H, Govaerts A. Cell-mediated immunity in diabetes mellitus. Clinical and experimental immunology. 1974;18(4):461.
Alba-Loureiro TC, Munhoz CD, Martins JO, Cerchiaro GA, Scavone C, Curi R, Sannomiya P. Neutrophil function and metabolism in individuals with diabetes mellitus. Brazilian Journal of Medical and Biological Research. 2007;40:1037-44.
Hornef MW, Wagner HJ, Kruse A, Kirchner H. Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo. Clinical Diagnostic Laboratory Immunology. 1995;2(2):209-13.
Xu DZ, Huang KL, Zhao K, Xu LF, Shi N, Yuan ZH, Wen YM. Vaccination with recombinant HBsAg–HBIG complex in healthy adults. Vaccine. 2005;23(20):2658-64.
Sujal Kumar Bokshi, Ashesh Chowdhury. Study between seromarkers (IL-2, IFN-γ and anti-HBS titer) and type 2 diabetic subjects with duration of diabetes following hepatitis B vaccination. Acta Scientific MICROBIOLOGY (ISSN: 2581-3226). 2023;6(8).
Rostami N, Ghafari V, Samaei H. Comparison of immune response to hepatitis B vaccine between term and preterm infants at birth.
Awofeso N. Hepatitis B vaccination in prisons. Bulletin of the World Health Organization. 2002;80(7):569-74.
Pukhalsky AL, Shmarina GV, Bliacher MS, Fedorova IM, Toptygina AP, Fisenko JJ, Alioshkin VA. Cytokine profile after rubella vaccine inoculation: Evidence of the immunosuppressive effect of vaccination. Mediators of inflammation. 2003;12(4): 203-7.
Larsen CE, Xu J, Lee S, Dubey DP, Uko G, Yunis EJ, Alper CA. Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine. 2000;18(26):3021-30.
Kindt TJ, Goldsby RA, Osborne BA, Kuby J. Kuby immunology. Macmillan; 2007.
Nohria A, Rubin RH. Cytokines as potential vaccine adjuvants. Cytokines in the Treatment of Infectious Diseases: Options for the Modulation of Host Defense. 1995;261-9.
Doyle MV, Newell AD, Nunberg JH and White TJ 2000, Human IL-2 at Vaccine Adjunt, USA Patent.
Van Sloten ML, Hayon . Babai , Zakay-Rones Z. Wagner E. Strom G, Kedar E. Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines, Biochim Biophys Acta; 2001.
Barash C, Conn MI, DiMarino AJ, Marzano J, Allen ML. Serologic hepatitis B immunity in vaccinated health care workers. Archives of internal medicine. 1999;159(13):1481-3.